Huge congratulations to Dr Annalisa Jenkins OBE, a member of Etira’s Board of Directors, who has been appointed an Officer of the Order of the British Empire (OBE) in The King’s New Year Honours for her services to life sciences.This…
https://etira.life/wp-content/uploads/2026/01/Dr-Annalisa.jpg500500Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2026-01-09 08:00:542026-01-10 16:42:31Etira Board Member recognized in 2026 King’s New Year Honors
San Antonio, TX – November 18, 2025. Etira Founder Professor Ratna Vadlamudi delivered a compelling, deeply personal narrative as the featured speaker at the Health Cell State of the Industry event at the Tobin Center in San Antonio. He reflected…
Philadelphia, PA – July 16, 2025: In an article just published in Clinical Leader magazine entitled "How An Australia-First Strategy Cut 63% From Our R&D Spend", Etira CEO Russell Hayward explains how our strategic decision to conduct…
https://etira.life/wp-content/uploads/2025/07/australia-rd-savings-etira.jpg14501530Carlton Hoythttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngCarlton Hoyt2025-07-16 08:27:302026-01-02 10:45:53Etira CEO Featured In Clinical Leader for R&D Efficiency
Dallas, Texas — June 26, 2025: Etira, a clinical-stage biopharmaceutical company aiming to develop cancer therapies, announced today that the first patient has been successfully treated at Dose Level Four (DL4) in its ongoing Phase 1 clinical…
https://etira.life/wp-content/uploads/2024/08/clinical-trial-sign.jpg7131000Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2025-06-26 13:14:192026-01-02 10:58:01Progress in ERX-315 Phase 1 Clinical Trial
Sydney, Australia – June 2, 2025: Etira, a clinical-stage biopharmaceutical company focused on developing cancer therapies, announced the activation of a new trial site at Macquarie University Hospital (MUH) in Sydney, New South Wales. The…
Chicago, IL – April 30, 2025:Presenters of two abstracts with preclinical data on ERX-208 and ERX-315 have won awards at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago.Adriana Baker, who presented…
https://etira.life/wp-content/uploads/2025/04/AACR-2025-graphic-2K-e1746033763417.jpg10171083Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2025-04-30 11:25:242025-04-30 12:09:39Research on Etira drugs win awards at AACR 2025
Chicago, IL - April 23, 2025:
Three abstracts with preclinical data on ERX-208 and ERX-315 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in San Diego. These abstracts will establish ERX-208 as…
https://etira.life/wp-content/uploads/2025/04/Unknown.png14001266Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2025-04-24 14:25:482026-01-02 11:01:32Preclinical data on ERX-208 and ERX-315 to be presented at AACR 2025
Adelaide, Australia – March 17, 2025: Etira, a clinical-stage biopharmaceutical company developing new cancer therapies, has now activated a second site for recruitment of patients for the ERX-315-001 clinical trial at Cancer Research South…
https://etira.life/wp-content/uploads/2025/03/image.png6821096Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2025-03-17 11:03:202026-01-02 11:03:55Second site activated for ERX-315 trial
Sydney, Australia – February 20, 2025: Etira, a clinical-stage biopharmaceutical company developing new cancer therapies, announced today that a patient has been successfully dosed at Dose Level Three (DL3) of ERX-315 in its Phase 1 trial…
Dallas, TX - December 2, 2024: Etira, a clinical-stage biotechnology company pioneering novel approaches to treating cancer by inducing endoplasmic reticulum stress, today announced the appointment of Etira Co-Founder, Ganesh Raj, M.D., Ph.D.,…
https://etira.life/wp-content/uploads/2024/12/image.png566658Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2024-12-02 10:06:322026-01-02 11:08:23Dr. Raj appointed as Etira Chief Medical Officer
Patients must be at least 18 years of age at the time of signing the informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial, and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective
Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Adequate baseline organ function and hematologic function
Life expectancy >3 months
Exclusion criteria
Systemic anti-cancer therapy within 4 weeks of first dose of study drug
Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
Uncontrolled intercurrent illnesses
Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.
Etira Board Member recognized in 2026 King’s New Year Honors
NewsEtira Founder’s Scientific Journey Highlighted
NewsEtira CEO Featured In Clinical Leader for R&D Efficiency
NewsProgress in ERX-315 Phase 1 Clinical Trial
NewsEtira Expands Clinical Trial Sites
NewsResearch on Etira drugs win awards at AACR 2025
NewsPreclinical data on ERX-208 and ERX-315 to be presented at AACR 2025
NewsSecond site activated for ERX-315 trial
NewsERX-315 Phase 1 Clinical Trial Update
NewsDr. Raj appointed as Etira Chief Medical Officer
News